BioMarin rated at peer perform by Thomas Weisel

BioMarin Pharmaceutical, Inc. was given a peer perform rating by Thomas Weisel Partners LLC analyst Maneesh Jain on news of Naglazyme's European approval. Management provided 2006 Naglazyme sales guidance of $28 million to $32 million for worldwide sales. Shares of the Novato, Calif., biopharmaceutical company were up 77 cents, or 7.03%, at $11.73 on volume of 3,153,517 shares versus the three-month running average of 451,518 shares. (Nasdaq: BMRN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.